title: Treatment ofClostridium difficileinfection: recent trial results.
abstract: Clostridium difficileis a major cause of infection worldwide and is associated with increasing morbidity and mortality in vulnerable patient populations. Metronidazole and oral vancomycin are the currently recommended therapies for the treatment ofC. difficileinfection (CDI) but are associated with unacceptably high rates of disease recurrence. Novel therapies for the treatment of CDI and prevention of recurrent CDI are urgently needed. Important developments in the treatment of CDI are currently underway and include: novel antibacterial agents with narrower antimicrobial spectra of activity, manipulation of the gut microbiota and enhancement of the host antibody immune response.
authors.affiliation: Department of Medicine, Division of Infectious Diseases & International Health, Duke University Medical Center, Durham, NC, USA ; Duke Infection Control Outreach Network, Duke University Medical Center, Durham, NC, USA.
authors.forename: Sarah S
authors.initials: SS
authors.lastname: Lewis
authors.affiliation: Department of Medicine, Division of Infectious Diseases & International Health, Duke University Medical Center, Durham, NC, USA ; Duke Infection Control Outreach Network, Duke University Medical Center, Durham, NC, USA.
authors.forename: Deverick J
authors.initials: DJ
authors.lastname: Anderson
keywords: BI/NAP1/ribotype 027 strain; Clostridium difficile infection; fecal microbiota transplant; fidaxomicin; human microbiome